Professor Javier Crespo is a distinguished physician-scientist and academic leader in the field of digestive and liver diseases. Currently a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL, he has made significant contributions through over 400 original publications, more than 120 clinical trials, and leadership in numerous national and international research projects. With an H-index of 70 and over 30,000 citations, his work has had a profound global impact. He has played a pivotal role in national health strategies, including Spain’s Hepatitis C elimination plan, and served as President of major professional societies such as SEPD. A mentor to numerous doctoral and master’s students, he has also received multiple prestigious awards for his contributions to medicine and research. His leadership at Marqués de Valdecilla University Hospital earned repeated national recognition for excellence in digestive and hepatitis care.

Professional Profile 

Google Scholar
Scopus Profile
ORCID Profile 

Education

Professor Javier Crespo earned his Degree in Medicine and General Surgery from the University of Cantabria with an Outstanding qualification. He later obtained his Doctorate in Medicine in 1993, receiving the Extraordinary Doctorate Award for academic excellence. His formal education laid a strong foundation for a career marked by clinical rigor and academic depth. In addition to his medical qualifications, he has been accredited as a Professor by ANECA (the Spanish National Agency for Quality Assessment and Accreditation). His academic journey reflects not only excellence in performance but also an enduring commitment to scientific learning and advancement. His scholarly trajectory is rooted in a lifelong dedication to the field of hepatology and digestive pathology, with an early focus on merging basic medical science with clinical research. These formative years have played a crucial role in shaping his influential career in medicine, teaching, and research.

Professional Experience

Professor Crespo has held several prestigious positions throughout his career. He is a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL. He served as Head of the Digestive Service at Marqués de Valdecilla University Hospital from 2010 to 2024. Additionally, he has played strategic roles in healthcare governance, including being a member of Spain’s National Strategic Plan against Hepatitis C since 2015 and coordinator of the AEEH National Liver Health Plan Challenge 2032. His leadership extends to professional societies—he served as President of the Spanish Society of Digestive Pathology (SEPD), President of the National Digestive Commission, and Secretary of the Spanish Association for the Study of the Liver. His professional career reflects a unique blend of clinical excellence, policy leadership, academic mentoring, and research management, making him one of the most respected figures in his specialty.

Research Interest

Professor Crespo’s primary research interests center around digestive and liver diseases, with a particular focus on hepatitis C, liver cirrhosis, and inflammatory bowel diseases. He has led more than 120 clinical trials across Phases I–III and participated in 15 national and 8 international competitive research projects. His translational approach bridges laboratory findings with clinical application, especially in hepatology. Under his leadership, the IDIVAL research group has produced high-impact findings in digestive pathology and liver disease progression. He has authored over 400 original scientific articles, with a strong presence in high-impact journals. His work is cited more than 30,000 times, and he holds an H-index of 70, underscoring his global influence. He is also actively involved in supervising doctoral and postgraduate theses, reflecting his dedication to advancing the next generation of researchers in gastroenterology. His research has contributed significantly to public health, particularly in the management and elimination of hepatitis C.

Award and Honor

Professor Javier Crespo has received numerous national and international awards that recognize both his scientific excellence and public health impact. Among his most prestigious accolades are the Elimination Champions 2023 International Award, granted by the Coalition for Global Hepatitis Elimination, and the International Award at the VI LIFE Forum for HCV Elimination in Lima (2024). Nationally, he has been honored with the Commendation of the Civil Order of Health, the SEPD Gold Medal, and the ACAD Gold Medal. He was also named an Illustrious Torrelaveguense in 2024. Under his leadership, the Digestive Service at Marqués de Valdecilla University Hospital received the Best in Class Award for several consecutive years for excellence in digestive and hepatitis care. His honors reflect not only scientific merit but also his dedication to clinical service and public health leadership, making him one of the most decorated professionals in his field.

Conclusion

In conclusion, Professor Javier Crespo is a highly accomplished and impactful leader in the fields of gastroenterology and hepatology. His career combines outstanding academic achievement, clinical leadership, and translational research excellence. With more than 30,000 citations and an H-index of 70, his scientific contributions have shaped current practices in liver disease treatment and public health strategies. He has held top-level positions in hospitals, universities, research institutes, and national health commissions, evidencing his multifaceted influence. Through his mentorship, he has cultivated a generation of researchers and clinicians, further extending his legacy. His work has not only garnered national and international recognition through prestigious awards but has also led to meaningful improvements in patient care, especially in hepatitis C management. Professor Crespo exemplifies the qualities of a visionary researcher, a compassionate physician, and a dedicated educator—making him exceptionally worthy of recognition such as the Best Researcher Award.

Publications Top Notes

• Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis

  • Authors: Not listed

  • Year: 2025

  • Citations: 3

• Letter to the Editor: Optimizing MASLD treatment—A “lead-in phase” before resmetirom

  • Authors: Not listed

  • Year: Not listed

  • Citations: 1

• Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation

  • Authors: Not listed

  • Year: 2025

• Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions

  • Authors: Not listed

  • Year: Not listed

  • Citations: 1

• A multisociety Delphi consensus statement on new fatty liver disease nomenclature

  • Authors: ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, …

  • Year: 2023

  • Citations: 4,096

• Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease

  • Authors: N Inohara, Y Ogura, A Fontalba, O Gutierrez, F Pons, J Crespo, K Fukase, …

  • Year: 2003

  • Citations: 2,245

• Modeling NAFLD disease burden in 8 countries (2016–2030)

  • Authors: C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, …

  • Year: 2018

  • Citations: 2,027

• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

  • Authors: HSA Newsome, PN Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, S Sanyal, …

  • Year: 2021

  • Citations: 1,673

• Obeticholic acid for the treatment of NASH: Phase 3 trial analysis

  • Authors: ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, …

  • Year: 2019

  • Citations: 1,286

• Elafibranor resolves NASH without fibrosis worsening

  • Authors: SA Ratziu, V Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, …

  • Year: 2016

  • Citations: 1,217

• Sofosbuvir and ribavirin in HCV genotypes 2 and 3

  • Authors: ER Zeuzem, S Dusheiko, GM Salupere, R Mangia, A Flisiak, RH Hyland, …

  • Year: 2014

  • Citations: 1,048

• A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis

  • Authors: Not listed

  • Year: 2024

  • Citations: 983

• Gene expression of TNF-α and TNF receptors in NASH patients

  • Authors: J Crespo, A Cayón, P Fernández‐Gil, M Hernández‐Guerra, M Mayorga, …

  • Year: 2001

  • Citations: 971

• Advancing the global public health agenda for NAFLD: Consensus statement

  • Authors: JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, …

  • Year: 2022

  • Citations: 683